secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2026-05-14T20:15:44+00:00
Accession:  0001493152-26-023095
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Biosciences Q1 2026 revenue $9.0M, thyroid revenue up 12% YoY; reaffirms 16% growth guidance
--------------------------------------------------------------------------------

- Q1 revenue $9.0M; GAAP down 22% YoY due to PancraGEN exit, but Pro Forma revenue up 14% to $9.0M from $7.9M.
- Adjusted EBITDA $1.6M (17% margin) vs $0.8M Pro Forma in prior year; operating income margin improved to 12% from 6% Pro Forma.
- Thyroid test volume increased 10% YoY; revenue per test up 3%; active accounts increased 5%.
- Gross margin expanded to 65% from 59% Pro Forma; company debt-free with $8.7M cash collections in Q1.
- Reaffirmed 2026 guidance of ~16% year-over-year thyroid revenue growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315226023095/0001493152-26-023095-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315226023095/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-023095

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer